Clinical Trial Update: Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Tocovid Suprabio 200mg in hepatic steatosis and non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Steatosis
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Tocovid Suprabio 200mg

Snippet

Sponsor: Yuen Kah Hay | Conditions: Hepatic Steatosis, NAFLD | Phase 2 | Status: COMPLETED